701
Participants
Start Date
September 4, 2019
Primary Completion Date
June 3, 2026
Study Completion Date
June 3, 2026
Lazertinib
Lazertinib will be administered orally.
Amivantamab
Amivantamab will be administered as an intravenous (IV) infusion.
Carboplatin
Carboplatin will be administered as IV infusion.
Pemetrexed
Pemetrexed will be administered as IV infusion.
Chung Shan Medical University Hospital, Taichung
National Cheng Kung University Hospital, Tainan City
Kaohsiung Medical University Chung Ho Memorial Hospital, Kaohsiung City
Hosp Univ Vall D Hebron, Barcelona
National Taiwan University Hospital, Taipei
Langone Health at NYC University, NYU School of Medicine, New York
Columbia University Medical Center, New York
CHU de la Timone, Marseille
Evangelische Lungenklinik Berlin, Berlin
Seoul National University Bundang Hospital, Seongnam-si
University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine, Philadelphia
San Gerardo Hospital, Monza
IRCCS Ospedale San Raffaele, Milan
Virginia Cancer Specialists, Fairfax
Pius-Hospital Oldenburg, Oldenburg
Hosp. Gral. Univ. Gregorio Maranon, Madrid
Hosp. Univ. Ramon Y Cajal, Madrid
Hosp Univ Fund Jimenez Diaz, Madrid
Hosp. Univ. 12 de Octubre, Madrid
Hosp Univ Hm Sanchinarro, Madrid
Institut Bergonie, Bordeaux
H. Lee Moffitt Cancer & Research Institute, Tampa
Hosp. Virgen Del Rocio, Seville
Universitaetsklinikum Essen, Essen
Ospedale S. Maria Delle Croci, Ravenna
Barbara Ann Karmanos Cancer Institute, Detroit
Uniklinik Köln, Cologne
Kliniiken der Stadt Köln gGmbH, Krankenhaus Köln-Mehrheim, Cologne
Lungenklinik Hemer, Hemer
Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt am Main
Washington University School Of Medicine, St Louis
Centre Leon Berard, Lyon
Robert-Bosch-Krankenhaus - Klinik Schillerhoehe, Stuttgart
Institut Curie, Paris
Istituto Nazionale Tumori Fondazione G. Pascale, Napoli
Asklepios Klinik Gauting GmbH - Asklepios Fachkliniken Munchen-Gauting, Gauting
Huntsman Cancer Institute, Salt Lake City
CHU De Poitiers, Poitiers
USC Norris Comprehensive Cancer Center, Los Angeles
Cedars Sinai Medical Center, West Hollywood
University of California Irvine, Orange
UCSF Helen Diller Comprehensive, San Francisco
HIA Begin, Saint-Mandé
Stanford University Medical Center, Stanford
Institut Gustave Roussy, Villejuif
Providence Portland Medical Center, Portland
University of Washington, Seattle
Beijing Cancer Hospital, Beijing
Shengjing Hospital Of China Medical University, Shenyang
The First Bethune Hospital of Jilin University, Changchun
Shanghai Chest Hospital, Shanghai
Central Hospital of Jinan, Jinan
Tianjin Medical University Cancer Institute and Hospital, Tianjin
Zhejiang Cancer Hospital, Hangzhou
Chongqing University Cancer Hospital, Chongqing
Hunan Cancer hospital, Changsha
Union Hospital Tongji Medical College of Huazhong University of Science and Technology, Wuhan
The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou
West China School of Medicine/West China Hospital, Sichuan University, Chengdu
The Second Affiliated Hospital of Kunming Medical University, Kunming
The First Affiliated Hospital of Xian Jiaotong University, Xi'an
Massachusetts General Hospital, Boston
Boston University Medical Center, Boston
Dana Farber Cancer Institute, Boston
Städtisches Krankenhaus Martha-Maria Halle-Dölau gGmbH, Halle
IRCCS Istituto Europeo di Oncologia, Milan
National Cancer Center Hospital, Chūōku
Kansai Medical University Hospital, Hirakata
National Cancer Center Hospital East, Kashiwa
Kobe City Medical Center General Hospital, Kobe
Aichi Cancer Center Hospital, Nagoya
Okayama University Hospital, Okayama
Shizuoka Cancer Center, Shizuoka
Oncologic Hospital, Puerto Rico Medical Center, Rio Piedras
Seoul National University Hospital, Seoul
Severance Hospital Yonsei University Health System, Seoul
Samsung Medical Center, Seoul
Hosp. Univ. Quiron Dexeus, Barcelona
Janssen Research & Development, LLC
INDUSTRY